Svar CRO & Alentis Therapeutics’ Journey
Svar Life Science CRO partners with Alentis Therapeutics, a Swiss biotech company known for groundbreaking work in oncology and fibrosis, supporting their pioneering work in the development of anti-Claudin-1 (CLDN1) therapies.
Over the course of more than forty studies since 2020, we have supported Alentis’ non-clinical and clinical programs, helping in navigating complex immunogenicity, pharmacokinetic, and biomarker studies with speed, insight, and precision.
Becoming the Go-to Partner for High-Stakes Studies
Alentis Therapeutics sought a CRO with a deep understanding of antibodies and ligand-binding assay design, a partner who could do more than just run assays. Svar proved to be the right scientific match among numerus competitors thanks to strong expertise in assay design and proactive approach to solving complex challenges.
“Svar’s expertise in ligand-binding assays gave us the confidence we needed and started what would become a long-term strategic partnership,” said Markus Meyer, Chief Operating Officer at Alentis Therapeutics. “They have supported the journey from TK/PK through ADA and biomarker studies in pre-clinical and clinical phases, and they have done it consistently well.”
“Svar CRO’s input went far beyond simple assay execution. They advised also on study design, sample timing, and data interpretation. Svar CRO helped shape critical decisions in our program.”
Marcus Meyer, PhD
Chief Operating Officer, Alentis Therapeutics
The Claudin-1 Company
Alentis Therapeutics is pioneering anti-Claudin-1 therapies, which are potential breakthrough treatments for CLDN1+ tumors and fibrotic diseases. Claudin-1 is an extraordinary target that plays a key role in many solid tumors and fibrosis, and Alentis is at the forefront of developing first-in-class antibody-drug conjugates and monoclonal antibodies to modify and reverse the course of these diseases.
Alentis’ vision to target Claudin-1 underscores their excellence in the biotech industry and their dedication to addressing serious and life-threatening conditions with unmet medical needs.
Strategic Partnership Beyond Execution
Alentis Therapeutics engages Svar not just as CROs but as a trusted collaborator. Over time, we became an extension of Alentis’ R&D team, scientifically sharp and operationally reliable.
“We’ve rarely seen a CRO so knowledgeable in antibody assays” continued Dr Meyer. “They immediately understood our challenges and had ideas for solutions.”
Flexible, Responsive, Reliable
With multiple overlapping studies and tight timelines, Alentis needed an agile partner that could answer its needs quickly. Our flexible, responsive and reliable approach allowed to develop the right strategy that could meet Alentis’ needs:
- Recurrent meetings to ensure continued alignment
- Flexible project planning allowing for rapid resourcing
- One dedicated project manager working cross-functionally
“Our flexibility, personalized support, and resource management made it possible to adapt to meet overlapping strict deadlines.”
Barbara Lettiero, PhD
Senior Scientist & Project Manager, Svar Life Science
Results That Matter
At Svar CRO Services, our mission is simple: deliver scientific excellence, act as true extension of our partners’ teams.
This initial collaboration proved that scientific excellence can outshine scale. Our tailored approach and deep assay expertise laid the groundwork for a strong and trusted relationship. We’re now continuing our partnership with further studies and new drug candidates, building on the success of our joint efforts.
“We don’t just deliver data, we help drive decisions - all to accelerate drug development programs that address real medical needs and bring innovative therapies to patients faster.”
Anna Karaszewska, MSc
Product Manager CRO Services, Svar Life Science
